Nimbus Organized Annual ADME Meeting
News Nov 22, 2005
"Discover the hidden properties!" was the slogan of the annual ADME meeting organized by Nimbus Biotechnology.
During this outstanding meeting scientists presented and discussed current strategies for ADME issues.
Dr. Keldenich (Bayer HealthCare AG, Germany) reported in his presentation about a correlation of membrane affinity measured by the well known TRANSIL® technology to the permeability determinate by double sink PAMPA for a subset of compounds.
He also pointed out that the TRANSIL® technology has additionally advantages like reliability and easiness of the assays for membrane affinity.
In this respect Dr. Schmitt (Bayer Technology Services, Germany) said in his presentation that the membrane affinity hide much additional information about a compound.
To discover those properties it is necessary to use this physicochemical data as an input parameter of physiology based pharmacokinetic modelling, so that the user is able to predict important ADME parameters like fraction absorbed, fraction unbound, volume of distribution or plasma/organ partitioning coefficients.
Wolfgang Lerch, CEO of NIMBUS Biotechnology, stated that, "The membrane affinity is a reliable, fast and easy to measure parameter which hide important information like a gold mine."
"During the meeting it was impressively demonstrated by several speakers that TRANSIL® ADME assays are extremely valuable for drug discovery."
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
Tuberculosis: Pharmacists Develop Substance to Counteract Antimicrobial ResistanceNews
Antimicrobial resistance is on the rise worldwide. This is becoming a problem for infectious diseases like tuberculosis as there are only a few active substances available to combat such diseases. Pharmacists have now found a way to increase the efficacy of a common tuberculosis agent while, at the same time, reducing resistance to it.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018